Preservation and Transfer of HBV Immunity After Allogeneic HSCT for SCD.
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
We hypothesize, that sickle cell disease (SCD) patients ending with mixed mononuclear
chimerism after non-myeloablative HSCT with alemtuzumab/TBI conditioning will preserve their
immune response to vaccinations administered prior to the transplantation and will therefore
not need to be revaccinated. Furthermore, we hypothesize, that SCD patients after
haploidentical HSCT can benefit from adoptive transfer of immunity from their donors.
To test the first hypothesis, we will vaccinate patients undergoing the alemtuzumab/TBI HSCT
with a hepatitis B virus (HBV) vaccine before the transplant. To test the second hypothesis,
we will vaccinate haploidentical and matched related donors prior to stem cell donation
against HBV. Neither the patient nor the donor may previously have been immunized against HBV
in all cohorts. Post-transplantation, we will be able to evaluate whether SCD patients
preserve their pre-transplant immune response in the post-transplantation period.
Furthermore, we will determine whether donors transfer their immunity to HSCT recipients with
SCD disease.
Phase:
N/A
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)